圣和散联合放射治疗中晚期食管癌临床观察

目的观察圣和散联合放射治疗中晚期食管癌的远期疗效.方法采用随机对照法,治疗组76例采用圣和散联合放射治疗,对照组73例采用单纯放射治疗,观察治疗前后临床症状、体征、瘤体变化,并检测外周血象、细胞免疫及心、肝、肾功能.随访5年以上.结果近期有效率治疗组为89.47%,对照组为贷.75%,两组比较有显著性差异(P＜0.01).1、3、5年生存率,治疗组依次为77.63%、40.79%和30.26%,明显优于对照组的41.10%、16.44%和9.59%(P＜0.05或P＜0.01).同时发现,圣和散能明显提高T淋巴细胞和NK细胞的活性,无明显心、肝、肾毒性.结论圣和散联合放射治疗能明显提高中晚期食管癌远期生存率,并有良好的免疫调整作用.

Clinical Observation on Therapeutic Effect of Shenghe Powder Plus Radiation in Treating Advanced Esophageal Cancer

To explore the effect of Shenghe powder(SHP)plus radiotherapy for advanced esophageal cancer Methods:In a randomized controlled study,76 cases(treated group)received SHP plus radiotherapy,73 cases(control group)received radiotherapy alone.The changes of symptoms and tumor size were observed,and the peripheral blood picture and cytoimmunologic and vital functions determined before and after treatments.Follow-up studies were carried out for more than 5 years.Results:The short-term response rate(CR PR)of the treated group was 89.47%,that of control group was 65.75% with significant differences( P <0.01).The CD 3,CD 4,CD 4/CD 8 and NK activities raised markedly after treatment in comparing with those before treatment and control group( P <0.05 or 0.01).The 1-,3-,5-year survival rates in treated group were 77.63%,40.79%and 30.26%respectively,significantly higher than those of 41.10%,16.44%and 9.59%in control( P <0.05 or 0.01),without any injuries on heart,liver and kidney function. Conclusion:SHP exhibited good effect in immunoregulation,the combined use of SHP and radiotherapy could markedly improve the survival of advanced esophageal cancer.